Ebola virus disease

Kimberley Steeds, Ebola vaccine trial team member, in the Ebola vaccine laboratory, Donka Hospital in Conakry, Guinea.

Ebola outbreak Democratic Republic of the Congo 2017

13 May 2017 - The WHO Regional Director for Africa, Dr Matshidiso Moeti today visited Kinshasa to discuss with national authorities and partners ways to mount a rapid, effective and coherent response in order to stop the ongoing Ebola outbreak.

WHO/S. Hawkey
WHO Director-General visits families who participated in the Ebola vaccine trial, Guinea

Ebola vaccines for Guinea and the world: photos

5 May 2017 -- More than 11 000 people in Guinea participated in a WHO-led trial to develop the world’s first vaccine against Ebola virus disease. The ground-breaking trial, which ended in January 2016, resulted in a vaccine that is highly protective against the deadly virus. Dr Margaret Chan, Director-General of WHO, visited some of the communities who participated in the vaccine trial in the city of Conakry.

WHO/S. Cumberland
Dr Chan in Guinea: Ebola vaccine success

Leaders gather in Guinea to celebrate Ebola vaccine successes

4 May 2017 -- “The world is far better prepared for another Ebola outbreak,” said Dr Margaret Chan, WHO Director-General, today at a celebratory event to recognize the Governments and people of the three most-affected countries for their contribution to the control of the Ebola outbreak in 2014-2015.

WHO/S. Hawkey
Infection prevention training, during the Ebola outbreak, Guinea

Sharing lessons from a milestone year: WHO Sierra Leone's 2016 Progress Report

March 2017 -- WHO continues to support countries like Sierra Leone, that were struck by the Ebola outbreak: prevent, detect, and respond to epidemics and ensure zero cases of Ebola Virus Disease (EVD); and deliver continuous care for Ebola-affected persons and survivors.

WHO
Ebola vaccine trial

Ebola vaccine provides protection, trial confirms

23 December 2016 – An experimental Ebola vaccine was highly protective against the deadly virus in a major trial, according to results published today in The Lancet. The vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year. The vaccine, called rVSV-ZEBOV, was studied in a trial involving 11 841 people in Guinea during 2015.

S. Hawkey
Ebola vaccine trial team follows-up with a vaccine trial participant, Katongourou, Guinea

After Ebola in West Africa: Unpredictable risks, preventable epidemics

September 2016 -- Empirical and modeling studies conducted during the West African epidemic have shown that large epidemics of Ebola virus disease are preventable — a rapid response can interrupt transmission and restrict the size of outbreaks, even in densely populated cities. The critical question now is how to ensure that populations and their health services are ready for the next outbreak, wherever it may occur.

WHO/S. Hawkey



Health systems

Health systems recovery

Recovering from an outbreak requires getting essential health services back up and running, and addressing the weaknesses of the health system. WHO's is working with affected countries in rebuilding their health systems.

Survivors

Ebola survivors programme

Ebola survivors need comprehensive support for the medical and psychosocial challenges they face and also to minimize the risk of continued Ebola virus transmission.

Situation reports: DRC

Review of the situation and an assessment of the response measured against the core indicators. The reports include tables, maps, and data on total number of Ebola cases in the Democratic Republic of Congo.


Preparedness. R&D

Preparedness for emergencies

WHO is working with countries in implementing plans to prevent and respond to a possible epidemic of Ebola virus disease.

R&D Blueprint

Ebola clinical trials are bringing the world close to having its first safe and effective Ebola vaccine, while researchers are learning more every day about the long-term effects of Ebola on survivors.